Aigen Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Aigen Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,840	Closed	-$197K	–	998
2023 Q4	$197K	Buy	+13,840	New	+$196K	0.04%	669
2023 Q1	–	Sell	-83,491	Closed	-$1.3M	–	826
2022 Q4	$1.3M	Buy	+83,491	New	+$1.17M	0.18%	144
2022 Q3	–	Sell	-94,747	Closed	-$1.33M	–	753
2022 Q2	$1.33M	Buy	94,747 +70,191	+286%	+$1M	0.22%	134
2022 Q1	$352K	Sell	24,556 -264	-1%	-$3.88K	0.06%	338
2021 Q4	$337K	Buy	+24,820	New	+$348K	0.02%	753
2021 Q3	–	Sell	-36,261	Closed	-$610K	–	652
2021 Q2	$610K	Sell	36,261 -3,989	-10%	-$67.9K	0.11%	201
2021 Q1	$735K	Buy	+40,250	New	+$724K	0.1%	223
2020 Q3	–	Sell	-167,092	Closed	-$3M	–	1101
2020 Q2	$3M	Buy	167,092 +134,296	+409%	+$2.41M	0.38%	46
2020 Q1	$498K	Buy	32,796 +8,468	+35%	+$153K	0.07%	418
2019 Q4	$480K	Buy	+24,328	New	+$465K	0.08%	326

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aigen Investment Management's TAK Position: Q1 2024 in Review

Aigen Investment Management sold out of Takeda Pharmaceutical (TAK) in Q1 2024, closing a stake of 13,840 shares — an estimated $197K sold.

Aigen Investment Management first reported a position in TAK in Q4 2019 and held it in 10 quarters. The position peaked at $3M in Q2 2020. 315 funds tracked by Wall St. Rank hold TAK as of Q1 2024.

Aigen Investment Management reported no remaining Takeda Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Aigen Investment Management sold 13,840 Takeda Pharmaceutical shares in Q1 2024, an estimated $197K.
Aigen Investment Management first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 10 quarters.
Aigen Investment Management's Takeda Pharmaceutical position peaked at $3M in Q2 2020.
315 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.